181 related articles for article (PubMed ID: 30397488)
21. A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study).
Iwata T; Yoshino I; Yoshida S; Ikeda N; Tsuboi M; Asato Y; Katakami N; Sakamoto K; Yamashita Y; Okami J; Mitsudomi T; Yamashita M; Yokouchi H; Okubo K; Okada M; Takenoyama M; Chida M; Tomii K; Matsuura M; Azuma A; Iwasawa T; Kuwano K; Sakai S; Hiroshima K; Fukuoka J; Yoshimura K; Tada H; Nakagawa K; Nakanishi Y;
Respir Res; 2016 Jul; 17(1):90. PubMed ID: 27450274
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of IFN-γ, sCD163, CCL2 and CXCL10 involved in acute exacerbation of idiopathic pulmonary fibrosis.
Gui X; Qiu X; Tian Y; Xie M; Li H; Gao Y; Zhuang Y; Cao M; Ding H; Ding J; Zhang Y; Cai H
Int Immunopharmacol; 2019 May; 70():208-215. PubMed ID: 30851700
[TBL] [Abstract][Full Text] [Related]
23. Study protocol: exploring the efficacy of cyclophosphamide added to corticosteroids for treating acute exacerbation of idiopathic pulmonary fibrosis; a randomized double-blind, placebo-controlled, multi-center phase III trial (EXAFIP).
Naccache JM; Montil M; Cadranel J; Cachanado M; Cottin V; Crestani B; Valeyre D; Wallaert B; Simon T; Nunes H
BMC Pulm Med; 2019 Apr; 19(1):75. PubMed ID: 30971235
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of corticosteroid and intravenous cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis: A propensity score-matched analysis.
Hozumi H; Hasegawa H; Miyashita K; Yasui H; Suzuki Y; Kono M; Karayama M; Furuhashi K; Hashimoto D; Enomoto N; Fujisawa T; Inui N; Nakamura Y; Yokomura K; Nakamura H; Suda T
Respirology; 2019 Aug; 24(8):792-798. PubMed ID: 30803100
[TBL] [Abstract][Full Text] [Related]
25. Prognostic differences among patients with idiopathic interstitial pneumonias with acute exacerbation of varying pathogenesis: a retrospective study.
Kato M; Yamada T; Kataoka S; Arai Y; Miura K; Ochi Y; Ihara H; Koyama R; Sasaki S; Takahashi K
Respir Res; 2019 Dec; 20(1):287. PubMed ID: 31852459
[TBL] [Abstract][Full Text] [Related]
26. Prognostic evaluation of serum ferritin in acute exacerbation of idiopathic pulmonary fibrosis.
Enomoto N; Oyama Y; Enomoto Y; Mikamo M; Karayama M; Hozumi H; Suzuki Y; Kono M; Furuhashi K; Fujisawa T; Inui N; Nakamura Y; Suda T
Clin Respir J; 2018 Aug; 12(8):2378-2389. PubMed ID: 29873202
[TBL] [Abstract][Full Text] [Related]
27. Acute exacerbations of idiopathic pulmonary fibrosis: Does clinical stratification or steroid treatment matter?
Cuerpo S; Moisés J; Hernández-González F; Benegas M; Ramirez J; Sánchez M; Agustí À; Sellares J
Chron Respir Dis; 2019; 16():1479973119869334. PubMed ID: 31431063
[TBL] [Abstract][Full Text] [Related]
28. Acute Exacerbation of Idiopathic Pulmonary Fibrosis.
Kishaba T
Medicina (Kaunas); 2019 Mar; 55(3):. PubMed ID: 30884853
[TBL] [Abstract][Full Text] [Related]
29. Acute exacerbations of fibrotic interstitial lung diseases.
Suzuki A; Kondoh Y; Brown KK; Johkoh T; Kataoka K; Fukuoka J; Kimura T; Matsuda T; Yokoyama T; Fukihara J; Ando M; Tanaka T; Hashimoto N; Sakamoto K; Hasegawa Y
Respirology; 2020 May; 25(5):525-534. PubMed ID: 31426125
[TBL] [Abstract][Full Text] [Related]
30. Prognostic evaluation by oxygenation with positive end-expiratory pressure in acute exacerbation of idiopathic pulmonary fibrosis: A retrospective cohort study.
Suzuki A; Taniguchi H; Ando M; Kondoh Y; Kimura T; Kataoka K; Matsuda T; Yokoyama T; Sakamoto K; Hasegawa Y
Clin Respir J; 2018 Mar; 12(3):895-903. PubMed ID: 28026113
[TBL] [Abstract][Full Text] [Related]
31. Incidence of acute exacerbation of idiopathic pulmonary fibrosis in patients receiving antifibrotic agents: Real-world experience.
Isshiki T; Sakamoto S; Yamasaki A; Shimizu H; Miyoshi S; Nakamura Y; Homma S; Kishi K
Respir Med; 2021 Oct; 187():106551. PubMed ID: 34343721
[TBL] [Abstract][Full Text] [Related]
32. Predictors of acute exacerbation in biopsy-proven idiopathic pulmonary fibrosis.
Kishaba T; Hozumi H; Fujisawa T; Nei Y; Enomoto N; Sugiura H; Kitani M; Suda T
Respir Investig; 2020 May; 58(3):177-184. PubMed ID: 32205147
[TBL] [Abstract][Full Text] [Related]
33. Acute exacerbation in interstitial lung disease.
Alhamad EH; Cal JG; Alrajhi NN; AlBoukai AA
Ann Thorac Med; 2021; 16(2):178-187. PubMed ID: 34012485
[TBL] [Abstract][Full Text] [Related]
34. Risk factors of acute exacerbation of idiopathic pulmonary fibrosis.
Kondoh Y; Taniguchi H; Katsuta T; Kataoka K; Kimura T; Nishiyama O; Sakamoto K; Johkoh T; Nishimura M; Ono K; Kitaichi M
Sarcoidosis Vasc Diffuse Lung Dis; 2010 Jul; 27(2):103-10. PubMed ID: 21319592
[TBL] [Abstract][Full Text] [Related]
35. Serum decorin is a potential prognostic biomarker in patients with acute exacerbation of idiopathic pulmonary fibrosis.
Nikaido T; Tanino Y; Wang X; Sato Y; Togawa R; Kikuchi M; Misa K; Saito K; Fukuhara N; Kawamata T; Rikimaru M; Umeda T; Morimoto J; Koizumi T; Suzuki Y; Hirai K; Uematsu M; Minemura H; Fukuhara A; Sato S; Saito J; Yokouchi H; Kanazawa K; Shibata Y
J Thorac Dis; 2018 Sep; 10(9):5346-5358. PubMed ID: 30416782
[TBL] [Abstract][Full Text] [Related]
36. Prognosis of patients with acute exacerbation of combined pulmonary fibrosis and emphysema: a retrospective single-centre study.
Ikuyama Y; Ushiki A; Kosaka M; Akahane J; Mukai Y; Araki T; Kitaguchi Y; Tateishi K; Urushihata K; Yasuo M; Yamamoto H; Hanaoka M
BMC Pulm Med; 2020 May; 20(1):144. PubMed ID: 32434532
[TBL] [Abstract][Full Text] [Related]
37. Exposure to PM
Tahara M; Fujino Y; Yamasaki K; Oda K; Kido T; Sakamoto N; Kawanami T; Kataoka K; Egashira R; Hashisako M; Suzuki Y; Fujisawa T; Mukae H; Suda T; Yatera K
Respir Res; 2021 Mar; 22(1):80. PubMed ID: 33711988
[TBL] [Abstract][Full Text] [Related]
38. Acute exacerbation of postoperative idiopathic pulmonary fibrosis in a patient with lung cancer caused by invasive mechanical ventilation: A case report.
Qiu B; Zhang ZL; Zhao XH; Wang CM; Wang T; Wang ZP
Heliyon; 2023 Nov; 9(11):e21538. PubMed ID: 38027643
[TBL] [Abstract][Full Text] [Related]
39. Time for Prevention of Idiopathic Pulmonary Fibrosis Exacerbation.
Richeldi L
Ann Am Thorac Soc; 2015 Nov; 12 Suppl 2():S181-5. PubMed ID: 26595737
[TBL] [Abstract][Full Text] [Related]
40. Acute Exacerbation of Idiopathic Pulmonary Fibrosis with Lung Cancer: A Comparative Analysis of the Incidence, Survival Rate, and CT Findings with the Patients without Lung Cancer.
Cho B; Kang H; Kim JH; Park JG; Park S; Yun JH
Taehan Yongsang Uihakhoe Chi; 2020 May; 81(3):688-700. PubMed ID: 36238614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
